Epidemiological suggestions that the shingles vaccine might protect against dementia keep rolling in. Pascal Geldsetzer, Stanford University, presented his group’s latest findings at this year’s ...
Is it three steps forward one step back for blood tests? At the 18th Clinical Trials on Alzheimer’s Disease, held December 1–4 in San Diego, new data on the FDA-approved Fujirebio Lumipulse plasma ...
In Pick’s disease, as in Alzheimer’s disease and frontotemporal dementia, tangled tau spells trouble. In this subtype of FTD, abnormal clumps of three-repeat tau called Pick bodies abound in neurons.
Aβ and tau get much of the glory in Alzheimer’s disease, but the disease is far more complex than two proteins. Scientists know, for example, that lipid metabolism goes awry, but identifying ...
This is a knock-in (KI) mouse model carrying a L444P mutation in the endogenous Gba (glucocerebrosidase [GC] or acid β-glucosidase) gene (Liu et al., 1998). The GBA1 protein is the lipid-degrading ...
Focused ultrasound with microbubbles is a noninvasive procedure that transiently opens the blood-brain barrier (BBB) using low-intensity sound waves. The openings reseal within 24 hours. Using MRI to ...
The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
With anti-amyloid antibodies now consistently hitting their target, tau immunotherapy represents the next frontier. In Alzheimer’s disease, tau tangles correlate far more closely with cognitive ...
Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...
In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback